The purpose of this study is to establish a safe and effective dose of CAR-T cells for patients with relapsed or refractory mantle cell Lymphoma or other indolent Non-Hodgkin lymphoma
Your blood will be collected so that the manufacturing process to make modified T cells can begin. The modified study cells will hopefully be more effective at killing your cancer cells than your body's normal immune cells. The study team will do blood tests and other procedures to confirm it is safe for you to get the modified study cells. If it is safe, you will complete three days of pre-treatment (chemotherapy) that will prepare your body to accept the study cells better. You will then receive the study cell infusion. You will have to stay near the hospital after infusion and will be seen frequently in clinic for follow-up visits that may include lab tests, imaging, or biopsies of your tumor. You will continue follow up visits based on how well you have responded to the study treatment.
Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Natalie Grover
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Lymphoma)
18-0726